Persistence of anti-islet ADCC after manifestation of type-1 (insulin-dependent) diabetes.
ADCC (antibody-dependent cellular cytotoxicity) against xenogenic islets in vitro has frequently been found with mononuclear blood cells and heat inactivated autologous serum from newly diagnosed Type-1 diabetics. Anti-islet ADCC, as measured by enhanced 51Cr-release of islets after a 6h-incubation, leads to functional alteration of islets such as a decrease in insulin content and in leucine incorporation. In a follow-up investigation over at least three years it was demonstrated that anti-islet ADCC in vitro disappears, if there is no more C-peptide secretion in vivo. Furthermore, anti-islet ADCC has also not been found in long-term Type-1 diabetics who had no C-peptide secretion but an acutely stimulated immune system due to infectious diseases. An acute immunocytolytic process against pancreatic beta cells in vivo seems to be the precondition for anti-islet ADCC in vitro.
Köhler
E
E
Central Institute of Diabetes Gerhardt Katsch, Karlsburg, GDR.
Knospe
S
S
Besch
W
W
Michaelis
D
D
Rjasanowski
I
I
D000293:Adolescent; D000328:Adult; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology*; D002096:C-Peptide / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000276:immunology* / Q000378:metabolism; D005260:Female; D006801:Humans; D007515:Islets of Langerhans / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D007930:Leucine / Q000378:metabolism; D008297:Male
D002096:C-Peptide; D007930:Leucine